Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Susceptibility of pediatric acute lymphoblastic leukaemia to STAT3 inhibition depends on p53 induction

ABSTRACT: Susceptibility of pediatric acute lymphoblastic leukaemia to STAT3 inhibition depends on p53 induction

PROVIDER: PRJNA882410 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21639803.fastq.gz	Fastqsanger.gz
	SRR21639804.fastq.gz	Fastqsanger.gz
	SRR21639805.fastq.gz	Fastqsanger.gz
	SRR21639806.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Susceptibility of pediatric acute lymphoblastic leukaemia to STAT3 inhibition depends on p53 induction

Project description:Advances in the clinical management of pediatric B cell Acute Lymphoblastic Leukemia (B-ALL) have dramatically improved outcomes for this disease. However, relapsed and high-risk disease still contribute to significant numbers of treatment failures. Development of new, broad range therapies is urgently needed for these cases. We previously reported the susceptibility of ETV6-RUNX1+ pediatric B-ALL to inhibition of signal transducer and activator of transcription 3 (STAT3) activity. In the present study, we demonstrate that pharmacological or genetic inhibition of STAT3 results in p53 induction and that CRISPR-mediated TP53 knockout substantially reverses susceptibility to STAT3 inhibition. Furthermore, we demonstrate that sensitivity to STAT3 inhibition in patient-derived xenograft (PDX) B-ALL samples is not restricted to any particular disease subtype, but rather depends on TP53 status, the only resistant samples being TP53 mutant. Induction of p53 following STAT3 inhibition is MDM2-independent and exhibits synergistic in vitro and in vivo anti leukemia activity when combined with MDM2 inhibition. Taken together with the relatively low frequency of TP53 mutations in this disease, these data support the future development of combined STAT3/MDM2 inhibition in the therapy of refractory and relapsed pediatric B-ALL.

2024-04-10 | GSE213766 | GEO

Gene expression changes in REH following STAT3 inhibition by shRNA

Project description:STAT3 (Signal transducer and activator of transcription 3) expression is associated with with t(12;21) acute lymphoblastic leukaemia (ALL) and it is crucial for the survival of the t(12;21) ALL . Our study investigated the STAT3 regulated pathways and discovered a novel STAT3-TP53 axis in B-ALL. In order to determine the STAT3 regulated pathways in t(12;21) ALL cells, we performed RNAseq analysis on the Pre-B Acute Lymphoblastic Leukemia (ALL) cell line REH following shRNA-mediated STAT3 knockdown

2024-01-31 | GSE179332 | GEO

Gene expression changes in REH following STAT3 pharmacological inhibition

2024-01-31 | GSE179333 | GEO

Genome-wide analysis of basal gene expression analysis of pediatric acute lymphoblastic leukaemia xenograft cells

2015-04-01 | GSE63988 | GEO

Transcriptomic profiling of 2 cell lines from Down-Syndrome children with Acute Lymphoblastic Leukaemia (DS-ALL)

Project description:Two cell lines derived from 2 Down Syndrome children who developed Acute Lymphoblastic Leukaemia were profiled at the transcriptomic level (bulk RNAseq) and compared against their Patient-Derived Xenograft (PDX) of origin.

2024-07-10 | GSE245056 | GEO

Genome-wide analysis of basal gene expression analysis of pediatric acute lymphoblastic leukaemia xenograft cells

Project description:Analysis of patient-derived xenograft cells at the basal level. A panel of T- and BCP-ALL pediatric leukaemia xenograft cells were utilised to further understand the biology of pediatric leukaemia. Total RNA were isolated from patient-derived xenograft cells. Illumina beadchip HT12 were utilised

2015-04-01 | E-GEOD-63988 | biostudies-arrayexpress

ChIP-chip by array of human T-acute lymphoblastic leukaemia cells using AcH3 antibodies

Project description:T-ALL Xenograft Histone Modification at ERG locus: The cells used are human T-acute lymphoblastic leukaemia cells that have been propagated in NOD/SCID mice. T-ALL8,T-ALL16, T-ALL27, T-ALL29, T-ALL30 and T-ALL31 are cells from six different patients. Normalized data files containing chromosome 21 data are available on the FTP site for this experiment in the E-MTAB-431.additional.zip archive.

2012-01-01 | E-MTAB-431 | biostudies-arrayexpress

Transcriptional response in acute lymphoblastic leukaemia cells to bone marrow microenvironment

Project description:Glucocorticoids (GCs) and topoisomerase II inhibitors are used in the treatment of acute lymphoblastic leukaemia (ALL) due to their ability to induce cell death in lymphoid cells. GC-induced apoptosis is mediated by the glucocorticoid receptor (GR), whereas topoisomerase II inhibitors cause DNA damage and activate sensors of DNA damage including the tumour suppressor p53. In order to shed light on the role of the microenvironment in cell death and identify determinants of drug sensitivity we performed transcriptomic analysis in ALL cells treated with the synthetic glucocorticoid dexamethasone, and the topoisomerase II inhibitor etoposide combined with bone marrow-derived conditioned media (CM).

2017-08-30 | E-MTAB-4761 | biostudies-arrayexpress

Genome-scale DNA methylation profiling of TEL/AML positive childhood acute lymphoblastic leukaemia

Project description:DNA methylation profiling of 48 samples to determine a DNA methylation signature specific to leukaemic bone marrow samples. Matching Leukaemia bone marrow and day 28 remission bone marrow or post induction follow up (follow up up to 2 years post induction) genomic DNA were extracted from archived microscope smear slides from 11 children diagnosed with TEL/AML positive Acute Lymphoblastic Leukaemia (ALL). Unmatched bone marrow samples from an additional 8 children were also analysed. Primary tissue control samples from CD34+ and CD19+ bone marrow from adult and childhood samples as well as model cell lines (cancer and non cancerous) were compared to primary diseased samples. Disease specific DNA methylation changes were identified from these results and then verified using SEQUENOM EpiTYPER.

2012-12-31 | GSE29189 | GEO

Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia

Project description:High frequencies of blasts in primary acute lymphoblastic leukaemia (ALL) samples have the potential to induce leukaemia and to engraft mice. However, it is unclear how individual ALL cells each contribute to drive leukaemic development in a bulk transplant and the extent to which these blasts vary functionally. We used cellular barcoding as a fate mapping tool to track primograft ALL blasts in vivo. Our results show that high numbers of ALL founder cells contribute at similar frequencies to leukaemic propagation over serial transplants, without any clear evidence of clonal succession. These founder cells also exhibit equal capacity to home and engraft to different organs, although stochastic processes may alter the composition in restrictive niches. Our findings enhance the stochastic stem cell model of ALL by demonstrating equal functional abilities of singular ALL blasts and show that successful treatment strategies must eradicate the entire leukaemic cell population.

2020-04-24 | GSE149170 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data